AbbVie reported a strong third quarter, with revenue reaching $15.78 billion, a 9% year-over-year increase, and non-GAAP net income of $1.86 per share, both surpassing analyst estimates, largely driven by blockbuster drugs like Skyrizi and Rinvoq. However, the company's stock declined over 4% as investors reacted negatively to its raised 2025 adjusted net income guidance of $10.61-$10.65 per share, which, despite being an increase, still fell short of the consensus analyst estimate of $10.86 per share.
AbbVie (ABBV) reported a robust third quarter, with revenue reaching $15.78 billion, a 9% year-over-year increase, and non-GAAP net income of $1.86 per share, both surpassing consensus analyst estimates of $15.58 billion and $1.78 per share, respectively. Despite these strong headline figures, the stock declined over 4% in the trading session, significantly underperforming the S&P 500's 0.3% gain, indicating investor dissatisfaction. The revenue beat was primarily driven by the strong performance of key blockbuster drugs, with Skyrizi experiencing a 47% increase in net revenue to $4.7 billion and Rinvoq advancing 35% to $2.2 billion. However, the negative market reaction stemmed from the company's updated 2025 adjusted net income guidance, which, while raised to $10.61-$10.65 per share from $10.38-$10.58, critically fell below the consensus analyst estimate of $10.86 per share. CEO Robert Michael highlighted "significant momentum across key areas of our portfolio" and progress in advancing the pipeline for long-term growth. This positive operational commentary contrasts with the market's cautious tone, which is heavily influenced by the guidance shortfall relative to elevated analyst expectations, resulting in a mildly negative sentiment for ABBV.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
